Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Taipei Exchange - Delayed Quote TWD

Mercury Biopharmaceutical Corporation (6932.TWO)

Compare
12.95
-0.25
(-1.89%)
At close: April 11 at 2:07:50 PM GMT+8
Loading Chart for 6932.TWO
  • Previous Close 13.20
  • Open 12.00
  • Bid 12.45 x --
  • Ask 12.95 x --
  • Day's Range 12.30 - 13.15
  • 52 Week Range 10.10 - 17.60
  • Volume 277,101
  • Avg. Volume 761,902
  • Market Cap (intraday) 5.36B
  • Beta (5Y Monthly) -2.66
  • PE Ratio (TTM) --
  • EPS (TTM) -0.10
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Mercury Biopharmaceutical Corporation engages in the development of drugs for unmet needs in Taiwan. The company develops StackDose platform, a drug development platform to produce new dosage forms with precise time-controlled dissolution, precise site absorption, and various dosage adjustments to enhance the bio-availability of active pharmaceutical ingredients to reduce the dosage of drugs and its side effects. It develops drugs for treating erectile dysfunction, pulmonary hypertension, sleep disorder, benign prostatic hyperplasia, angina pectoris, migraine, anti-hypertension, and analgesic. The company was founded in 2019 and is based in New Taipei City, Taiwan.

merdury.com

--

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 6932.TWO

View More

Performance Overview: 6932.TWO

Trailing total returns as of 4/11/2025, which may include dividends or other distributions. Benchmark is TSEC CAPITALIZATION WEIGHTED ST (^TWII) .

YTD Return

6932.TWO
0.77%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
15.22%

1-Year Return

6932.TWO
19.81%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
5.90%

3-Year Return

6932.TWO
90.51%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
14.55%

5-Year Return

6932.TWO
90.51%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
92.26%

Compare To: 6932.TWO

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 6932.TWO

View More

Valuation Measures

Annual
As of 4/11/2025
  • Market Cap

    5.36B

  • Enterprise Value

    5.14B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    936.65

  • Price/Book (mrq)

    16.55

  • Enterprise Value/Revenue

    893.42

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -6.98%

  • Return on Equity (ttm)

    -11.79%

  • Revenue (ttm)

    5.75M

  • Net Income Avi to Common (ttm)

    -43.41M

  • Diluted EPS (ttm)

    -0.10

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    264.89M

  • Total Debt/Equity (mrq)

    12.95%

  • Levered Free Cash Flow (ttm)

    -27.32M

Research Analysis: 6932.TWO

View More

Company Insights: 6932.TWO

Research Reports: 6932.TWO

View More
Waiting for permission
Allow microphone access to enable voice search

Try again.